The Centers for Disease Control and Prevention (CDC) Office of Public Health Preparedness and Response (OPHPR) intends to negotiate a sole source contract with Emergint BioSolutions under authority of Federal Acquisition Regulation (FAR) Subpart 6.302-1, Other Than Full and Open Competition procedures and FAR Part 12, Acquisition of Commercial Items, for the acquisition of vaccinia immune globulin (VIG). Only Emergint BioSolutions can provide the product as they are currently the only manufacturer.
This is a notice of intent and is not a request for competitive quotes or proposals. No solicitation is available. Firms that believe they can meet the requirement are encouraged to identify themselves and provide a substantive statement with descriptive literature and any other supporting information to the Contracting Officer within fifteen (15) business day of publication of this notice. All information received within 15 day of publication of this synopsis will be considered by the Government to determine if the more than one firm can meet the Government's requirements and is capable of providing technically acceptable services. Responses to this posting must be submitted in writing via e-mail only. A determination not to compete the described requirement based upon responses to this notice is solely within the discretion of the Federal Government. Information received will be considered solely for the purpose of determining whether or not to conduct a competitive procurement. Any questions or comments should be directed via e-mail ONLY to Lauren Peel at [email protected]. Thank you for your interest.

Bid Protests Not Available